Completed PHASE2 INTERVENTIONAL 3-arm NCT04405245

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Phase 2 Multi-Center, Double-Masked, Randomized, 28-Day Study to Assess the Efficacy, Safety and Tolerability of Single or Twice Daily Doses of AKB-9778 Ophthalmic Solution as an Adjunct to Latanoprost in Patients With Ocular Hypertension (OHT) or Open Angle Glaucoma (OAG)

Sponsor: EyePoint Pharmaceuticals, Inc.

Conditions Ocular Hypertension Primary Open Angle Glaucoma

Interventions AKB-9778 4% Latanoprost ophthalmic solution Placebo

Updated 9 times since 2020 Last updated: May 1, 2023 Started: Jun 6, 2020 Primary completion: Nov 5, 2020 Completion: Nov 5, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Ocular Hypertension and Primary Open Angle Glaucoma and is currently completed. EyePoint Pharmaceuticals, Inc. leads this study, which shows 9 recorded versions since 2020 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2
Feb 2021 — Jun 2023 [monthly]

Completed PHASE2

Status: Recruiting → Completed

▶ Show 4 earlier versions

Jan 2021 — Feb 2021 [monthly]

Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2
Jul 2020 — Sep 2020 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jun 2020 — Jul 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EyePoint Pharmaceuticals, Inc.

Data source: EyePoint Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Charlotte, United States , Cincinnati, United States , Cleveland, United States , Cranberry Township, United States , Inglewood, United States , Kingston, United States , Largo, United States , Memphis, United States , Mission Hills, United States and 11 more locations